MX2020001254A - Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor raf. - Google Patents

Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor raf.

Info

Publication number
MX2020001254A
MX2020001254A MX2020001254A MX2020001254A MX2020001254A MX 2020001254 A MX2020001254 A MX 2020001254A MX 2020001254 A MX2020001254 A MX 2020001254A MX 2020001254 A MX2020001254 A MX 2020001254A MX 2020001254 A MX2020001254 A MX 2020001254A
Authority
MX
Mexico
Prior art keywords
inhibitor
tyrosine kinase
combination
egfr tyrosine
generation egfr
Prior art date
Application number
MX2020001254A
Other languages
English (en)
Inventor
MOODY Susan
Petruzzelli Lilli
Engelman Jeffrey
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2020001254A publication Critical patent/MX2020001254A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención está relacionada con una combinación farmacéutica que comprende (a) un inhibidor de tirosina quinasa del EGFR de tercera generación y (b) un inhibidor Raf, en particular, para usarse en el tratamiento de un cáncer, en particular, un cáncer de pulmón. Esta invención también está relacionada con usos de dicha combinación para la preparación de un medicamento para el tratamiento de un cáncer; métodos para tratar un cáncer en un sujeto que los necesita que comprenden administrar a dicho sujeto una cantidad conjuntamente terapéuticamente eficaz de dicha combinación; composiciones farmacéuticas que comprenden dicha combinación y empaques comerciales para estas.
MX2020001254A 2017-08-03 2018-08-01 Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor raf. MX2020001254A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762540595P 2017-08-03 2017-08-03
PCT/IB2018/055792 WO2019026007A1 (en) 2017-08-03 2018-08-01 THERAPEUTIC ASSOCIATION OF THIRD GENERATION TYFRSINE KINASE INHIBITOR AND RAF INHIBITOR

Publications (1)

Publication Number Publication Date
MX2020001254A true MX2020001254A (es) 2020-03-20

Family

ID=63405289

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001254A MX2020001254A (es) 2017-08-03 2018-08-01 Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor raf.

Country Status (18)

Country Link
US (1) US20200237773A1 (es)
EP (1) EP3661516A1 (es)
JP (1) JP2020529411A (es)
KR (1) KR20200036880A (es)
CN (1) CN110996960A (es)
AU (1) AU2018311523A1 (es)
BR (1) BR112020001916A2 (es)
CA (1) CA3069564A1 (es)
CL (1) CL2020000270A1 (es)
IL (1) IL272350A (es)
JO (1) JOP20200014A1 (es)
MX (1) MX2020001254A (es)
PH (1) PH12020500096A1 (es)
RU (1) RU2020108192A (es)
SG (1) SG11201913249SA (es)
TW (1) TW201909920A (es)
WO (1) WO2019026007A1 (es)
ZA (1) ZA201908392B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3183982A1 (en) * 2020-06-25 2021-12-30 Stefanie Fluckiger-Mangual A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclc
CN111991559B (zh) * 2020-09-03 2022-03-22 中山大学 受体酪氨酸激酶抑制剂在制备预防和/或治疗新型冠状病毒感染药物中的应用
WO2023141659A2 (en) * 2022-01-24 2023-07-27 The Trustees Of Columbia University In The City Of New York Targeting s100a9-aldh1a1-retinoic acid signaling to suppress brain relapse in egfr-mutant lung cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
KR102112885B1 (ko) * 2012-08-07 2020-05-19 노파르티스 아게 B-raf 억제제, egfr 억제제 및 임의로 pi3k-알파 억제제를 포함하는 제약 조합물
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) * 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa

Also Published As

Publication number Publication date
JOP20200014A1 (ar) 2022-10-30
JP2020529411A (ja) 2020-10-08
IL272350A (en) 2020-03-31
CN110996960A (zh) 2020-04-10
SG11201913249SA (en) 2020-02-27
PH12020500096A1 (en) 2020-09-14
AU2018311523A1 (en) 2020-01-16
BR112020001916A2 (pt) 2020-07-28
TW201909920A (zh) 2019-03-16
KR20200036880A (ko) 2020-04-07
WO2019026007A1 (en) 2019-02-07
CA3069564A1 (en) 2019-02-07
CL2020000270A1 (es) 2020-08-28
ZA201908392B (en) 2021-05-26
US20200237773A1 (en) 2020-07-30
EP3661516A1 (en) 2020-06-10
RU2020108192A (ru) 2021-09-03

Similar Documents

Publication Publication Date Title
MX2019012884A (es) Terapia de combinacion.
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
SA519402217B1 (ar) مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2019001920A (es) Arn la terapia contra el cancer.
PH12018500642A1 (en) Anti-garp antibody
SG10201902664RA (en) Combination therapy for treating cancer
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
PH12016502353A1 (en) Pharmaceutical composition
WO2016109217A3 (en) Btk inhibitors
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2019003134A (es) Terapia de combinacion.
TW201613577A (en) Pharmaceutical combinations
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.